54346-35-9

Basic information

• Product Name: 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol
• Synonyms: 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol;8-Bromo-2-(methylsulfanyl)pyrazolo[1,5-a][1,3,5]-triazin-4-ol
• CAS NO: 54346-35-9
• Molecular Formula: C6H5BrN4OS
• Molecular Weight: 261.103
• Mol File: 54346-35-9.mol
• Article Data: 7

Chemical Properties

• Appearance: /
• Density: 2.166g/cm³
• Refractive Index: 1.859
• PKA: 5.69±0.20(Predicted)
• CAS DataBase Reference: 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol(54346-35-9)
• EPA Substance Registry System: 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol(54346-35-9)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 54346-35-9(Hazardous Substances Data)

Usage

General Description

8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol is a chemical compound with the molecular formula C6H5BrN4OS. It is a pyrazolo-triazinol derivative that contains a bromine atom and a methylthio group. 8-Bromo-2-(methylthio)pyrazolo[1,5-a][1,3,5]triazin-4-ol is used in pharmaceutical research and development, particularly in the study of its potential biological activities and therapeutic applications. Its structure and properties make it a promising candidate for the development of new drugs and medicinal compounds. It is important to handle this chemical with care due to potential hazards associated with its properties.

InChI:InChI=1/C6H5BrN4OS/c1-13-5-9-4-3(7)2-8-11(4)6(12)10-5/h2H,1H3,(H,9,10,12)

Upstream product

• 34683-00-6 ethyl N-[(1H-pyrazol-5-yl)carbamothioyl]carbamate 
• 34682-99-0 2-sulfanylidene-2,3-dihydropyrazolo[1,5-a][1,3,5]triazin-4(1H)-one 
• 54346-18-8 2-(methylsulfanyl)-3H-pyrazolo[1,5-a][1,3,5]triazin-4-one 
• 54346-18-8 2-(methylsulfanyl)pyrazolo[1,5-a][1,3,5]triazin-4-ol 
• 34682-99-0 2-sulfanylpyrazolo[1,5-a][1,3,5]triazin-4-ol 
• 948575-57-3 C₇H₉BrN₄O₂S 
• 948575-60-8 C₅H₃BrN₄SO 
• 74-88-4 methyl iodide 
• 948575-60-8 1,3-dihydro-8-bromopyrazolo[1,5-a][1,3,5]triazin-2-thioxo-4-one 

Downstream Products

• 54346-33-7 8-bromo-2-(methylthio)-4-chloropyrazolo<1,5-a>-1,3,5-triazine 

Relevant articles and documents

PYRAZOLOTRIAZINES

The present invention provides compounds of general formula (I), in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

PYRAZOLOPYRAZINES ACTING ON CANCERS VIA INHIBITION OF CDK12

The present invention provides compounds of general formula (I) in which X, R1, R2 and R3 are as described and defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of hyperproliferative disorders such as cancer disorders, as a sole agent or in combination with other active ingredients.

PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES AS SELECTIVE INHIBITOR OF CYCLIN DEPENDENT KINASE

The present invention relates to pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[l,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of cell proliferative diseases, inflammatory diseases, immunological diseases, cardiovascular diseases and infectious diseases. Furthermore, the present invention is directed towards pharmaceutical compositions containing at least one of the pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives and/or pharmaceutically acceptable salts thereof.